Navigation Links
Sinovac Reports Unaudited Second Quarter 2011 Financial Results
Date:8/12/2011

3,000 of interest and financing expenses, $132,000 loss on disposal of equipment, $38,000 of other income and $891,000 of income tax expense.  Net income attributable to stockholders for the second quarter of 2011 was $1.3 million, or $0.02 per diluted share, as compared to $1.0 million, or $0.02 per diluted share, in the same period of 2010.

As of June 30, 2011, Sinovac's cash and cash equivalents totaled $70.3 million, compared to $101.6 million at December 31, 2010.  Short-term investments were $22.4 million, compared to $1.5 million at December 31, 2010. The Company invests in short-term investments with principal and income guaranteed.

Financial Review for the Six Months Ended June 30, 2011 Sales for the six-month period of 2011 were $20.3 million, up 38.3% from $14.7 million for the same period quarter of 2010. During the six-month period of 2011, Sinovac recorded $7.7 million in pandemic influenza vaccine sales on prior year order.  

Sinovac's sales breakdown by product was as follows.Six months ended June 30,2011

2010SalesHepatitis vaccines

$12,562,124

$11,757,576Influenza vaccines

7,774,567

2,950,029Total

$ 20,336,691$ 14,707,605Gross profit for the six month period of 2011 was $13.9 million, with a gross margin of 68.2%, compared to $12.0 million and a gross margin of 81.9% for the same period of 2010.  After deducting depreciation of land use rights and amortization of licenses and permits, the gross margin was 66.9% and 80.5% for the six-month period of 2011 and 2010, respectively. The gross profit margin was adversely affected by the revenue recognition in the six-month period of 2011 of the prior pandemic flu vaccine order that had a lower gross margin than other vaccine products.

Selling, general and administrative expenses for the six-month period of 2011 were $9.1 million, compared to $7.1 million in the same period of 2010. SG&A expe
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Sinovac Announces Management Changes
2. Sinovac Holds 2011 Annual Shareholders Meeting
3. Sinovac Appoints Kenneth Lee to Board of Directors
4. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
5. Sinovac Reports Unaudited First Quarter 2011 Financial Results
6. Sinovac Presents at Two Investor Conferences in May 2011
7. Sinovac Files Annual Report on Form 20-F
8. Sinovac Participates in UBS Greater China Healthcare Corporate Day
9. Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
10. Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV)
11. Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very ... King as its new Chief Executive Officer.  Mark was ... which he has overseen the company,s four facilities in ... Costa Rica.  Mr. King joined Tegra Medical in 2012 with ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... , ARDEE, Ireland, Nov. 19 Warner ... of its previously announced secondary offering of 20,000,000 of its ... per share. The selling shareholders include funds affiliated with ... by CCMP Capital) and Thomas H. Lee Partners, L.P., certain ...
... , , LYON, France, Nov. 19 ... dangerous and illegal medicines, Operation Pangea II, involving 24 ... Organization,s International Medical Products Anti-Counterfeiting Taskforce (IMPACT) to highlight ... long global initiative resulted in a series of arrests ...
Cached Medicine Technology:Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... 2014U.S. military personnel who served in Iraq and ... brain injury (TBI) were compared to military personnel ... reasons. Differences in measures of overall disability, cognitive ... injury are reported in an article in ... Mary Ann Liebert, Inc., publishers. The article is ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
(Date:4/17/2014)... team led by researchers at UC Davis has shown ... key role in cell division, also boosts the mitochondrial ... time the complex has been shown to perform both ... excellent target to control cellular energy production, potentially advancing ... online today in the journal Developmental Cell . ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... today called for mass screening to identify people prone to ... stroke prevention policy. // ,On the eve of ... myths about strokes -- widely and wrongly believed to be ... ,"Unlike heart attacks, people know very little about strokes. It ...
... health care services provided to children with special health ... to be below their required need. //In addition, the ... their mental health care needs met. These are the ... by Harvard School of Public Health (HSPH) researchers, published ...
... were been faced by the doctors – a report from ... the BMA in Northern Ireland, say a similar case of ... A postal questionnaire addressed to all BMA workers in the ... ,More than half doctors participated in the survey revealed their ...
... Papilloma virus is a major cause of uterine cancer. According ... 70 % of Brazil’s uterine cancer cases//. Hence the Brazilian ... HPV. After the positive test results then the government plans ... are planning to conduct a campaign to vaccinate Brazilian women ...
... being organized to increase awareness of the effects of alcohol ... of drinking// are being highlighted as part of drug action ... alcohol spectrum disorders that cause physical and mental disabilities in ... the incidence of fetal alcohol spectrum disorders in Kimberley is ...
... Health had reported on Thursday that a second Dutch person ... disease, last year a woman died from the disease. ... not however disclose any further details about the patient to ... that eating contaminated meat products would have on all probabilities ...
Cached Medicine News:Health News:Health Care For Children With Special Needs Compromised 2Health News:Drug Action Week to Highlight Effects of Alcohol 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: